Talzenna for gBRCAm HER2-negative Locally Advanced or Metastatic Breast Cancer

February 13, 2019

Talzenna

Talzenna (talazoparib, Pfizer)

Indications: Adult Patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer.

Dosage: 1 mg singly oral daily dose until disease progression or unacceptable toxicity occurs

Contraindications: None

Click here for more prescribing information